Adicet Bio, Inc. (0HX7.L)
USD 0.68
(0.39%)
USD 0.68
(0.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 37.12 Million USD | -3.21% |
| 2022 | 38.35 Million USD | 7.1% |
| 2021 | 35.8 Million USD | -18.63% |
| 2020 | 44 Million USD | -69.0% |
| 2019 | 141.95 Million USD | 2375.2% |
| 2018 | 5.73 Million USD | 4.23% |
| 2017 | 5.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 34.29 Million USD | -7.62% |
| 2024 Q2 | 33.73 Million USD | -1.63% |
| 2023 Q3 | 38.58 Million USD | 0.02% |
| 2023 FY | 37.12 Million USD | -3.21% |
| 2023 Q4 | 37.12 Million USD | -3.78% |
| 2023 Q2 | 38.57 Million USD | -0.48% |
| 2023 Q1 | 38.75 Million USD | 1.06% |
| 2022 FY | 38.35 Million USD | 7.1% |
| 2022 Q3 | 36.64 Million USD | 0.02% |
| 2022 Q2 | 36.63 Million USD | 24.76% |
| 2022 Q1 | 29.36 Million USD | -17.99% |
| 2022 Q4 | 38.35 Million USD | 4.66% |
| 2021 Q1 | 45.81 Million USD | 4.1% |
| 2021 FY | 35.8 Million USD | -18.63% |
| 2021 Q2 | 40.43 Million USD | -11.74% |
| 2021 Q4 | 35.8 Million USD | -10.41% |
| 2021 Q3 | 39.97 Million USD | -1.15% |
| 2020 Q4 | 44 Million USD | 46.32% |
| 2020 Q3 | 30.07 Million USD | 14.5% |
| 2020 Q2 | 26.26 Million USD | 49.95% |
| 2020 Q1 | 17.51 Million USD | 17.85% |
| 2020 FY | 44 Million USD | -69.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | 141.95 Million USD | 2375.2% |
| 2019 Q4 | 14.86 Million USD | 0.0% |
| 2018 FY | 5.73 Million USD | 4.23% |
| 2017 FY | 5.5 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 94.051% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 70.563% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 93.991% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 85.978% |
| bluebird bio, Inc. | 424.62 Million USD | 91.258% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 46.014% |
| Imunon, Inc. | 8.53 Million USD | -335.148% |
| Editas Medicine, Inc. | 150.05 Million USD | 75.263% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.82% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 98.941% |
| Myriad Genetics, Inc. | 312.9 Million USD | 88.137% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 96.359% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 92.385% |
| Verastem, Inc. | 71.18 Million USD | 47.854% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.946% |
| Waters Corporation | 3.47 Billion USD | 98.932% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.928% |
| Biogen Inc. | 12.04 Billion USD | 99.692% |
| Nektar Therapeutics | 267.04 Million USD | 86.1% |
| Perrigo Company plc | 6.04 Billion USD | 99.386% |
| Dynavax Technologies Corporation | 375.02 Million USD | 90.102% |
| Illumina, Inc. | 4.36 Billion USD | 99.15% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -5.523% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 81.036% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 85.527% |
| Unity Biotechnology, Inc. | 37.29 Million USD | 0.461% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 98.036% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 54.969% |
| Evolus, Inc. | 209.68 Million USD | 82.297% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 7.721% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.478% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 94.382% |
| FibroGen, Inc. | 585.72 Million USD | 93.663% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 99.245% |
| OPKO Health, Inc. | 622.47 Million USD | 94.037% |
| Homology Medicines, Inc. | 118.53 Million USD | 68.684% |
| Geron Corporation | 146.12 Million USD | 74.597% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.084% |
| Exelixis, Inc. | 678.44 Million USD | 94.529% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -84.943% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -196.154% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 85.2% |
| Zoetis Inc. | 9.29 Billion USD | 99.601% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 90.656% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 24.516% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.279% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 23.377% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.574% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 98.457% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 67.669% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 97.75% |
| Blueprint Medicines Corporation | 918.64 Million USD | 95.959% |
| Insmed Incorporated | 1.66 Billion USD | 97.766% |
| TG Therapeutics, Inc. | 169.08 Million USD | 78.047% |
| Incyte Corporation | 1.59 Billion USD | 97.669% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 96.869% |